Due to the strong effects of semaglutide on TGFB1 and its histologically determined collagen-remodeling properties, we compared the hepatic transcriptome of semaglutide-treated Ldlr-/-.Leiden mice on FFD to a human dataset that differentiates NASH patients with severe fibrosis from NASH patients with mild fibrosis [22]. This evidence concerns the gene LDLR and metabolic dysfunction-associated steatohepatitis.